Infant Formula DHA ARA Body Composition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current infant formulas do not effectively increase lean body mass and reduce fat mass in infants without impacting overall growth, particularly in preterm infants, where there is a need for optimized nutritional composition to support neurodevelopment and body composition.
Innovation Solution
A nutritional formula containing docosahexaenoic acid (DHA) and arachidonic acid (ARA) is administered to infants, which increases lean body mass and reduces fat body mass without affecting overall growth, using sources such as fish oil, egg-derived oils, or fungal oils, ensuring adequate neurodevelopmental support.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If infant formulas are supplemented with DHA and EPA (no ARA), then neurodevelopment is supported, but lean body mass increases and fat mass is not reduced
Solution Approach 1:
The patent changes the fatty acid composition parameters by replacing EPA with ARA in the formula supplementation. This parameter change (from DHA+EPA to DHA+ARA) resolves the contradiction by achieving both neurodevelopmental support and improved body composition (increased lean mass and reduced fat mass) without the adverse effects observed with EPA supplementation.
Solution Approach 2:
The patent uses a composite approach by combining DHA and ARA in specific ratios (0.1-1.0% DHA and 0.2-1.0% ARA of total fatty acids) to create a synergistic effect. This composite fatty acid profile achieves both neuroprotection and metabolic benefits that neither fatty acid alone could provide, resolving the contradiction between neurodevelopment and body composition.
2Quantity of substance
If infant formulas are supplemented with DHA and ARA, then lean body mass increases and fat mass reduces, but overall growth rate may be affected
Solution Approach 1:
The patent optimizes the concentration parameters of DHA (0.1-1.0%) and ARA (0.2-1.0%) within specific ranges to achieve body composition improvements without compromising overall growth. These controlled parameter changes ensure that the fatty acid supplementation modifies body composition (increasing lean mass, reducing fat mass) while maintaining normal growth velocity.
3Productivity
If conventional infant formulas are used, then overall growth is maintained, but body composition is not optimized for lean mass and fat mass
Solution Approach 1:
The patent modifies the fatty acid composition parameters of conventional formulas by adding specific amounts of DHA (0.1-1.0%) and ARA (0.2-1.0%). This parameter modification allows the formula to maintain its ability to support overall growth while simultaneously optimizing body composition to increase lean mass and reduce fat mass, resolving the contradiction between growth maintenance and composition optimization.
Data Source
AI summary
Disclosed is a method of increasing lean body mass and reducing fat body mass in infants, said method comprising administration to an infant, term or preterm, a nutritional formula comprising a source of DHA and ARA. It has been found that the administration of DHA and ARA, or a source thereof, in infants can increase lean body mass and reduce fat body mass, when compared to an unsupplemented control formula, without impacting the total overall growth of the infant. This method is especially useful in preterm infants.